Clin2
NCT07215949Possibly a fitRecruiting

Zilucoplan for severe myasthenia gravis flare-ups

Generalized Myasthenia Gravis (gMG)

Treatments studied

Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.

This trial tests zilucoplan, a daily injection, to treat severe muscle weakness from myasthenia gravis that requires hospital care. It may help you recover faster and avoid needing a breathing tube.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
15 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are having a severe myasthenia gravis flare-up with swallowing, breathing, or neck weakness that needs hospital care.
  • You are at least 18 years old.
  • You test positive for AChR antibodies (a marker of myasthenia gravis).
  • You have not used a C5 inhibitor (like eculizumab) in the last 3 months, or it did not work for you.
  • You have not had rituximab in the last 9 months or started plasma exchange or IVIG in the last 4 weeks.
  • You are willing to get a meningococcal vaccine or take antibiotics to prevent infection.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06759948Not yet recruiting· Phase 1
Early study of GC012F injection for hard-to-treat myasthenia gravis

This early trial tests a new injection called GC012F in people with generalized myasthenia gravis that hasn't improved with standard treatments. The goal is to see if it can help reduce muscle weakness and improve daily life.

Shanghai, Shanghai Municipality
NCT07058298Recruiting· Early Phase 1
GC012F injection for hard-to-treat myasthenia gravis

This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.

Wuhan, Hubei
NCT06055959Recruiting· Phase 2/Phase 3
Zilucoplan for children with generalized myasthenia gravis

This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.

Chicago, Illinois
NCT06435312Enrolling by invitation· Phase 3
Studying zilucoplan for children with generalized myasthenia gravis

This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.

Milan
NCT06815133Recruiting
Study of zilucoplan in French patients with myasthenia gravis

This trial is for people in France with myasthenia gravis who are already taking zilucoplan. It tracks how well and how safely the medicine works over 3 months in everyday practice.

Nice, Alpes Maritimes
NCT05067348Recruiting· Phase 2
Tocilizumab for generalized myasthenia gravis symptoms

This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.

Beijing, Beijing Municipality

Hear when a new Generalized Myasthenia Gravis (gMG) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.